URGN (UroGen Pharma Ltd.) Stock Financials & Earnings | Market Cap Arena

URGN (UroGen Pharma Ltd.) Stock Financials & Earnings | Market Cap Arena

URGNUroGen Pharma Ltd.

Mkt Cap$927M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$110M

Net Income (TTM)-$153M

EPS (TTM)-$3.20

Free Cash Flow (TTM)-$163M

Gross Margin88.7%

Op. Margin-113.7%

Net Margin-139.8%

FCF Margin-148.2%

P/S Ratio (TTM)8.4x

P/E Ratio (TTM)—

YoY Rev Growth+21.4%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$17M	$15M	-$22M
Q2 23	$21M	$19M	-$15M
Q3 23	$21M	$18M	-$14M
Q4 23	$24M	$21M	-$15M
Q1 24	$19M	$17M	-$26M
Q2 24	$22M	$20M	-$26M
Q3 24	$25M	$23M	-$18M
Q4 24	$25M	$22M	-$28M
Q1 25	$20M	$18M	-$37M
Q2 25	$24M	$21M	-$41M
Q3 25	$27M	$24M	-$27M
Q4 25	$38M	$35M	-$19M

Valuation

Quarter	P/S	P/E
Q1 23	13.6x	—
Q2 23	12.8x	—
Q3 23	12.0x	—
Q4 23	11.2x	—
Q1 24	11.0x	—
Q2 24	10.9x	—
Q3 24	10.4x	—
Q4 24	10.3x	—
Q1 25	10.1x	—
Q2 25	9.8x	—
Q3 25	9.6x	—
Q4 25	8.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$26M	-$26M
Q2 23	-$20M	-$20M
Q3 23	-$17M	-$17M
Q4 23	-$13M	-$13M
Q1 24	-$32M	-$32M
Q2 24	-$24M	-$24M
Q3 24	-$28M	-$28M
Q4 24	-$14M	-$14M
Q1 25	-$42M	-$42M
Q2 25	-$40M	-$40M
Q3 25	-$42M	-$42M
Q4 25	-$38M	-$38M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$23K
Q2 23	$15K
Q3 23	$100K
Q4 23	$54K
Q1 24	$0
Q2 24	$84K
Q3 24	$96K
Q4 24	$115K
Q1 25	$44K
Q2 25	$141K
Q3 25	$87K
Q4 25	$17K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+26.7%	+10.5%
Q2 23	+27.3%	+3.4%
Q3 23	+29.5%	+0.5%
Q4 23	+30.1%	-0.6%
Q1 24	+9.2%	+13.5%
Q2 24	+3.4%	+30.6%
Q3 24	+20.9%	+24.4%
Q4 24	+4.4%	+36.9%
Q1 25	+7.8%	+28.4%
Q2 25	+10.8%	+37.7%
Q3 25	+9.0%	+28.3%
Q4 25	+54.0%	+9.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$2M	13.3%
Q2 23	$2M	10.5%
Q3 23	$2M	10.7%
Q4 23	$3M	11.1%
Q1 24	$3M	14.7%
Q2 24	$4M	16.3%
Q3 24	$3M	13.8%
Q4 24	$3M	13.4%
Q1 25	$3M	15.2%
Q2 25	$3M	11.3%
Q3 25	$3M	11.0%
Q4 25	$3M	8.3%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$12M	$24M
Q2 23	$12M	$22M
Q3 23	$10M	$22M
Q4 23	$11M	$25M
Q1 24	$15M	$27M
Q2 24	$15M	$30M
Q3 24	$11M	$29M
Q4 24	$15M	—
Q1 25	$20M	$35M
Q2 25	$19M	$43M
Q3 25	$14M	$38M
Q4 25	$14M	$39M

Revenue Segments

Quarter	Jelmyto
Q1 23	$17M
Q2 23	$21M
Q1 24	$19M
Q2 24	$22M
Q3 24	$25M
Q1 25	$20M
Q2 25	$24M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$37M	$29M	$65M
Q2 23	$20M	$27M	$47M
Q3 23	$119M	$28M	$147M
Q4 23	$96M	$42M	$138M
Q1 24	$132M	$33M	$165M
Q2 24	$220M	$21M	$241M
Q3 24	$125M	$125M	$250M
Q4 24	$172M	$65M	$237M
Q1 25	$104M	$92M	$196M
Q2 25	$93M	$64M	$157M
Q3 25	$90M	$37M	$127M
Q4 25	$111M	$10M	$120M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	23M	+0.8%
Q2 23	23M	+0.8%
Q3 23	32M	+37.7%
Q4 23	36M	+11.9%
Q1 24	33M	-7.7%
Q2 24	37M	+10.3%
Q3 24	43M	+17.1%
Q4 24	47M	+9.1%
Q1 25	47M	+0.8%
Q2 25	48M	+0.7%
Q3 25	48M	+0.7%
Q4 25	49M	+2.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	—	—
FY 16	—	—
FY 17	$194K	42
FY 18	$14K	78
FY 19	$104	173
FY 20	$63K	187
FY 21	$246K	195
FY 22	$322K	200
FY 23	$412K	201
FY 24	$385K	235
FY 25	$549	200K